Salerno Pharmaceuticals
Stories
-
FDA proposes withdrawal of approval for Salerno's Flolipid suspension
The FDA's Center for Drug Evaluation and Research proposes to withdraw approval of NDA 206679 for Flolipid suspension 20 mg/5 mL and 40 mg/5 mL because Salerno Pharmaceuticals has repeatedly failed to file required annual reports. Salerno may request a hearing on the proposal.